Home / Glossary

PERSONAL INJURY GLOSSARY

Comparative Negligence

A doctrine that reduces a plaintiff's damages by their percentage share of fault for the incident. Most US states use comparative negligence in some form.

Comparative negligence is a legal doctrine that lets a personal injury plaintiff recover damages even when partially at fault, with the recovery reduced by the plaintiff's percentage of responsibility. If a jury finds the plaintiff 20 percent at fault and the defendant 80 percent at fault, the plaintiff recovers 80 percent of the proven damages.

States apply comparative negligence in two main forms. Pure comparative negligence, used in California, Florida, New York, and a handful of other states, lets a plaintiff recover even if 99 percent at fault. Modified comparative negligence, used in Texas, Georgia, Nevada, and most other states, bars recovery once the plaintiff's fault crosses a threshold, usually 50 or 51 percent.

Comparative negligence shapes lien negotiation. If a verdict reduces damages by 30 percent for plaintiff fault, lien reductions become more important because the client's net pool shrinks. Lienholders that understand the dynamic often agree to proportional reductions, especially on pharmacy liens where the data is clean and the negotiation can resolve quickly.

CreoRx's pharmacy lien data supports comparative negligence cases. The firm has the complete fill history, the running balance, and the documented medication adherence that helps prove damages, while the lien itself can be negotiated down in proportion to the recovery the client ultimately receives.

See Also

contributory-negligence,plaintiff,settlement,lien-reduction,fault-state

See how CreoRx lien pharmacy solutions work for personal injury law firms

Book a 15 minute meeting and see how the pharmacy lien workflow runs end to end inside the CreoRx Attorney Portal, from intake to settlement reconciliation.

Book a 15 minute meetingLearn how pharmacy liens workBack to the glossary
Filevine integration coming soon → Join the Early Access List